Errata

1) Page 5, line 28 and 29  
   a) Patient follow up time was initially 7.4 years (Paper I and II), and after a patient  
      update it was extended to 12.4 years (Paper III).  
      i) Paper II should be moved to the right patient update category (first update with  
         follow-up of 7.4 years) as demonstrated above

2) Page 45, line 20  
   a) “Figure 13” should be corrected to “Figure 14”

3) Table 4, page 66:  
   a) A sentence has been added: “Numbers from the most recent patient update in Dec.  
      2015”

4) Page 93, line 12 – 14  
   a) In this thesis, both monoclonal and polyclonal antibodies were applied: Monoclonal:  
      pan-PGR (Paper I), ERβ (Paper II), PGRA and PGRB (Paper III). Polyclonal: pan-  
      ERα and aromatase (Paper II).  
      i) The pan-PGR antibody should have been classified as a monoclonal antibody as  
         demonstrated above

5) Page 105, second to last point in the box with “key discoveries in this thesis”  
   a) ERβ was an independent negative prognosticator for BF in TS, but not in TE, and was  
      not associated with CF or PCD  
      i) ERβ should have been correctly described as a negative prognosticator in TS, but  
         not in TE as demonstrated above

6) Table 7, page 81  
   a) The numbers for median BFFS, CFFS and PCDFS in the first patient update (Nov. 12)  
      has, in the submitted version, mistakenly been listed as the mean value instead of the  
      median. The correct median value is as listed below:  
      i) BFFS (months): 68.5  
      ii) CFFS (months): 83.7  
      iii) PCDFS (months): 87.9